Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1) II. Clinical aspects.

The simultaneous use of several drugs (polypharmacy) for the treatment of cancer, HIV, and other diseases and for multiple ailments of the elderly is a common practice in modern medicine. Co-administration of drugs may result in unwanted side effects. One reason for these side effects can be the altered function of transport proteins, especially of P-glycoprotein (Pgp), due to its simultaneous interaction with several drugs. We describe here some of the observed, unexpected side effects of polypharmacy in the clinic. We also describe intentional modulation of the function of Pgp that is introduced when facilitation of absorption of a drug through the intestines is needed and in cancer chemotherapy. In addition, we mention some methods of testing and ways by which doctors and patients can be alerted to potential side effects.

[1]  M. Ikeguchi,et al.  Modulation of multidrug resistance gene expression by dexamethasone in cultured hepatoma cells. , 1993, Endocrinology.

[2]  Oliver Burk,et al.  Nuclear Receptor Response Elements Mediate Induction of Intestinal MDR1 by Rifampin* , 2001, The Journal of Biological Chemistry.

[3]  J. Hochman,et al.  Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4. , 2000, The Journal of pharmacology and experimental therapeutics.

[4]  M. Gottesman,et al.  Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.

[5]  Yuichi Sugiyama,et al.  Comparative Studies on in Vitro Methods for Evaluating in Vivo Function of MDR1 P-Glycoprotein , 2001, Pharmaceutical Research.

[6]  J. Lankelma,et al.  Theoretical and practical considerations for the measurement of P-glycoprotein function in acute myeloid leukemia , 1997, Leukemia.

[7]  W. Kirch,et al.  P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. , 2000, International journal of clinical pharmacology and therapeutics.

[8]  Gordon H Bokhart,et al.  Rhabdomyolysis Causing AV Blockade Due to Possible Atorvastatin, Esomeprazole, and Clarithromycin Interaction , 2003, The Annals of pharmacotherapy.

[9]  Lawrence X. Yu,et al.  Vitamin E-TPGS Increases Absorption Flux of an HIV Protease Inhibitor by Enhancing Its Solubility and Permeability1 , 1999, Pharmaceutical Research.

[10]  H. Yamazaki,et al.  Assignment of the human cytochrome P-450 nifedipine oxidase gene (CYP3A4) to chromosome 7 at band q22.1 by fluorescence in situ hybridization , 1992, Japanese Journal of Human Genetics.

[11]  Evan D Kharasch,et al.  Evaluation of First‐Pass Cytochrome P4503A (CYP3A) and P‐Glycoprotein Activities Using Alfentanil and Fexofenadine in Combination , 2005, Journal of clinical pharmacology.

[12]  J. Molnár,et al.  Anti-psychotic drugs reverse multidrug resistance of tumor cell lines and human AML cells ex-vivo. , 1999, Cancer letters.

[13]  Terry R Stouch,et al.  Progress in understanding the structure-activity relationships of P-glycoprotein. , 2002, Advanced drug delivery reviews.

[14]  F. Sharom,et al.  Interaction of the P-glycoprotein Multidrug Transporter with Peptides and Ionophores (*) , 1995, The Journal of Biological Chemistry.

[15]  S Seeber,et al.  Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP) , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  Gerd Mikus,et al.  Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor EL. , 2002, British journal of clinical pharmacology.

[17]  M. Slovak,et al.  Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. , 1997, Blood.

[18]  W Vaalburg,et al.  A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. , 1999, Cancer research.

[19]  G. Dekan,et al.  MRP and MDR1 gene expression in primary breast carcinomas. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  M. Gottesman,et al.  Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.

[21]  M. Gottesman,et al.  P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential. , 2003, Cancer research.

[22]  H K Kroemer,et al.  The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. , 1999, The Journal of clinical investigation.

[23]  Yuichi Sugiyama,et al.  Impact of Drug Transporter Studies on Drug Discovery and Development , 2003, Pharmacological Reviews.

[24]  D. Ross,et al.  Synergistic reversal of multidrug-resistance phenotype in acute myeloid leukemia cells by cyclosporin A and cremophor EL. , 1994, Blood.

[25]  B. M. Forman,et al.  The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux , 2001, Nature Medicine.

[26]  L. Benet,et al.  The effect of water‐soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers , 1996, Clinical pharmacology and therapeutics.

[27]  Sean Ekins,et al.  A pharmacophore for human pregnane X receptor ligands. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[28]  C. Wandel,et al.  Increased drug delivery to the brain by P‐glycoprotein inhibition , 2000, Clinical pharmacology and therapeutics.

[29]  T. Fojo,et al.  Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  Peter Gwynne,et al.  Drug Discovery: 5 , 2002 .

[31]  C. Alderman,et al.  Digoxin–Itraconazole Interaction: Possible Mechanisms , 1997, The Annals of pharmacotherapy.

[32]  Oliver Burk,et al.  Cytochrome P450 3A4 and P‐glycoprotein Expression in Human Small Intestinal Enterocytes and Hepatocytes: A Comparative Analysis in Paired Tissue Specimens , 2004, Clinical pharmacology and therapeutics.

[33]  A. Schinkel,et al.  Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. , 2003, Advanced drug delivery reviews.

[34]  M. Bittner,et al.  Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. , 2000, Cancer research.

[35]  P. Meier,et al.  St John's Wort induces intestinal P‐glycoprotein/MDR1 and intestinal and hepatic CYP3A4 , 2000, Clinical pharmacology and therapeutics.

[36]  Y. Sugiyama,et al.  Inhibition of biliary excretion of methotrexate by probenecid in rats: quantitative prediction of interaction from in vitro data. , 2001, The Journal of pharmacology and experimental therapeutics.

[37]  S. Krähenbühl,et al.  Serious interaction between mibefradil and tacrolimus. , 1998, Transplantation.

[38]  A. Seelig,et al.  Structure-activity relationship of P-glycoprotein substrates and modifiers. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[39]  Increased systemic toxicity of sarcoma chemotherapy due to combination with the P-glycoprotein inhibitor cyclosporin. , 1998, International journal of clinical pharmacology and therapeutics.

[40]  I. Roninson,et al.  Localization of the human multiple drug resistance gene, MDR1, to 7q21.1 , 1987, Human Genetics.

[41]  M. Siepmann,et al.  The interaction of the calcium antagonist RO 40-5967 with digoxin. , 1995, British journal of clinical pharmacology.

[42]  T. Goggin,et al.  The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients , 2001, European Journal of Clinical Pharmacology.

[43]  D. L. Maxwell,et al.  Digoxin toxicity due to interaction of digoxin with erythromycin. , 1989, BMJ.

[44]  Yuichi Sugiyama,et al.  Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using 11C-verapamil. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[45]  D. Ross,et al.  Biochemical and clinical aspects of efflux pump related resistance to anti-cancer drugs. , 1998, Anticancer research.

[46]  Jiunn H. Lin,et al.  Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. , 2003, Advanced drug delivery reviews.

[47]  I. Pastan,et al.  Biochemical, cellular, and pharmacological aspects of the multidrug transporter. , 1999, Annual review of pharmacology and toxicology.

[48]  A. Rzhetsky,et al.  The human ATP-binding cassette (ABC) transporter superfamily. , 2001, Genome research.

[49]  J. Hochman,et al.  In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. , 2001, The Journal of pharmacology and experimental therapeutics.

[50]  M. Müller,et al.  Increased levels of the multidrug resistance protein in lateral membranes of proliferating hepatocyte-derived cells. , 1997, Gastroenterology.

[51]  Shiew-Mei Huang,et al.  FDA Evaluations Using In Vitro Metabolism to Predict and Interpret In Vivo Metabolic Drug‐Drug Interactions: Impact on Labeling , 1999, Journal of clinical pharmacology.

[52]  J. H. Beijnen,et al.  Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs , 1994, Cell.

[53]  I. Roninson,et al.  Human (MDR1) and mouse (mdr1, mdr3) P-glycoproteins can be distinguished by their respective drug resistance profiles and sensitivity to modulators. , 1995, Biochemistry.

[54]  P. S. Pine,et al.  Effect of combination of suboptimal concentrations of P‐glycoprotein blockers on the proliferation of MDR1 gene expressing cells , 1996, International journal of cancer.

[55]  L. Benet,et al.  Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. , 2002, The Journal of pharmacology and experimental therapeutics.

[56]  Y. Tanigawara,et al.  Digoxin-cyclosporin A interaction: modulation of the multidrug transporter P-glycoprotein in the kidney. , 1993, The Journal of pharmacology and experimental therapeutics.

[57]  C. Slapak,et al.  A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar Trihydrochloride (LY335979), Administered Intravenously in Combination with Doxorubicin in Patients with Advanced Malignancy , 2004, Clinical Cancer Research.

[58]  M. Caligiuri,et al.  Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  A. Breckenridge,et al.  Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV‐infected patients , 1997, AIDS.

[60]  J. Schellens,et al.  Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[61]  Y. Shao,et al.  Co-operative, competitive and non-competitive interactions between modulators of P-glycoprotein. , 1996, Biochimica et biophysica acta.

[62]  R. Advani,et al.  Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar) , 1999 .

[63]  A. Aszalos,et al.  Multidrug transporters as drug targets. , 2006, Current drug targets.

[64]  G Ecker,et al.  The importance of a nitrogen atom in modulators of multidrug resistance. , 1999, Molecular pharmacology.

[65]  L. Pecorino,et al.  Molecular Biology of Cancer: Mechanisms, Targets, and Therapeutics , 2005 .